The G1021A Substitution in the RYR1 Gene Does Not Cosegregate with Malignant Hyperthermia Susceptibility in a British Pedigree

Overview

Journal Am J Hum Genet

Publisher Cell Press

Specialty Genetics

Date 1997 Apr 1

PMID 9106529

Citations 4

Authors

A M Adeokun

S P West

F R Ellis

P J Halsall

P M Hopkins

A M Foroughmand

D E Iles

R L Robinson

A D Stewart

J L Curran

Affiliations

Soon will be listed here.

Abstract

A single base change in the RYR1 gene encoding the skeletal muscle ryanodine receptor (calcium-sensitive calcium-release channel of the sarcoplasmic reticulum), resulting in the substitution of G1021 by A, has been proposed to underlie malignant-hyperthermia (MH) susceptibility in as many as 10% of cases in the European population. As part of our mutation-screening program in MH-susceptible (MHS) individuals, we have investigated this substitution in individuals from 151 unrelated British MHS families and have detected G1021A heterozygotes in 7 families. This mutation was not found in 156 unrelated MH-negative (MHN) individuals. We also examined eight families with central core disease (CCD): the mutation did not occur in any family members of any disease status (affected or unaffected for CCD, MHS, or MHN). In one large family, the G1021A mutation was found but did not show complete cosegregation with MH susceptibility: it occurred in only 7/12 MHS individuals in the kinship, and susceptibility was inherited from parents who were G1021 homozygotes, as well as from parents who were heterozygotes. On the basis of these findings, it is clearly unreliable at present to offer presymptomatic DNA testing for MH status, even in families in which a mutation has been detected.

Citing Articles

Dietary Caffeine Synergizes Adverse Peripheral and Central Responses to Anesthesia in Malignant Hyperthermia Susceptible Mice.

Aleman M, Zhang R, Feng W, Qi L, Lopez J, Crowe C Mol Pharmacol. 2020; 98(4):351-363.

PMID: 32764093 PMC: 7491310. DOI: 10.1124/mol.120.119412.

Genetic epidemiology of malignant hyperthermia in the UK.

Miller D, Daly C, Aboelsaod E, Gardner L, Hobson S, Riasat K Br J Anaesth. 2018; 121(4):944-952.

PMID: 30236257 PMC: 6208294. DOI: 10.1016/j.bja.2018.06.028.

Next-generation Sequencing of RYR1 and CACNA1S in Malignant Hyperthermia and Exertional Heat Illness.

Fiszer D, Shaw M, Fisher N, Carr I, Gupta P, Watkins E Anesthesiology. 2015; 122(5):1033-46.

PMID: 25658027 PMC: 4472733. DOI: 10.1097/ALN.0000000000000610.

Genetic heterogeneity and HOMOG analysis in British malignant hyperthermia families.

Robinson R, Curran J, Hall W, Halsall P, Hopkins P, Markham A J Med Genet. 1998; 35(3):196-201.

PMID: 9541102 PMC: 1051241. DOI: 10.1136/jmg.35.3.196.

References

Dietrich W, Lander E, Smith J, Moser A, Gould K, Luongo C . Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell. 1993; 75(4):631-9. DOI: 10.1016/0092-8674(93)90484-8. View

Stewart A, Ball S, Halsall J, Hopkins P, Ellis F . No C1840 to T mutation in RYR1 in malignant hyperthermia. Hum Mutat. 1993; 2(4):330. DOI: 10.1002/humu.1380020418. View

Quane K, Keating K, Manning B, Healy J, Monsieurs K, Heffron J . Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: implications for diagnosis and heterogeneity studies. Hum Mol Genet. 1994; 3(3):471-6. DOI: 10.1093/hmg/3.3.471. View

Plassart E, Reboul J, Rime C, Recan D, Millasseau P, Eymard B . Mutations in the muscle sodium channel gene (SCN4A) in 13 French families with hyperkalemic periodic paralysis and paramyotonia congenita: phenotype to genotype correlations and demonstration of the predominance of two mutations. Eur J Hum Genet. 1994; 2(2):110-24. DOI: 10.1159/000472351. View

Iles D, Lehmann-Horn F, Scherer S, Tsui L, Olde Weghuis D, Suijkerbuijk R . Localization of the gene encoding the alpha 2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum Mol Genet. 1994; 3(6):969-75. DOI: 10.1093/hmg/3.6.969. View

Sudbrak R, Procaccio V, Klausnitzer M, Curran J, Monsieurs K, Van Broeckhoven C . Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. Am J Hum Genet. 1995; 56(3):684-91. PMC: 1801161. View

Iaizzo P, Lehmann-Horn F . Anesthetic complications in muscle disorders. Anesthesiology. 1995; 82(5):1093-6. DOI: 10.1097/00000542-199505000-00001. View

Vita G, Olckers A, Jedlicka A, George A, Heiman-Patterson T, Rosenberg H . Masseter muscle rigidity associated with glycine1306-to-alanine mutation in the adult muscle sodium channel alpha-subunit gene. Anesthesiology. 1995; 82(5):1097-103. DOI: 10.1097/00000542-199505000-00002. View

Deufel T, Sudbrak R, Feist Y, Rubsam B, Du Chesne I, Schafer K . Discordance, in a malignant hyperthermia pedigree, between in vitro contracture-test phenotypes and haplotypes for the MHS1 region on chromosome 19q12-13.2, comprising the C1840T transition in the RYR1 gene. Am J Hum Genet. 1995; 56(6):1334-42. PMC: 1801094. View

10.

OBrien R, Taske N, Hansbro P, Matthaei K, Hogan S, Denborough M . Exclusion of defects in the skeletal muscle specific regions of the DHPR alpha 1 subunit as frequent causes of malignant hyperthermia. J Med Genet. 1995; 32(11):913-4. PMC: 1051750. DOI: 10.1136/jmg.32.11.913. View

11.

Serfas K, Bose D, Patel L, Wrogemann K, Phillips M, Maclennan D . Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family. Anesthesiology. 1996; 84(2):322-9. DOI: 10.1097/00000542-199602000-00009. View

12.

KALOW W, Britt B, Terreau M, Haist C . Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet. 1970; 2(7679):895-8. DOI: 10.1016/s0140-6736(70)92069-6. View

13.

Ellis F, Keaney N, Harriman D, SUMNER D, Tyrrell J, Hargreaves J . Screening for malignant hyperpyrexia. Br Med J. 1972; 3(5826):559-61. PMC: 1785894. DOI: 10.1136/bmj.3.5826.559. View

14.

Kunkel L, Smith K, Boyer S, Borgaonkar D, Wachtel S, MILLER O . Analysis of human Y-chromosome-specific reiterated DNA in chromosome variants. Proc Natl Acad Sci U S A. 1977; 74(3):1245-9. PMC: 430660. DOI: 10.1073/pnas.74.3.1245. View

15.

Miller S, Dykes D, Polesky H . A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3):1215. PMC: 334765. DOI: 10.1093/nar/16.3.1215. View

16.

Weber J, May P . Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet. 1989; 44(3):388-96. PMC: 1715443. View

17.

Maclennan D, Duff C, Zorzato F, Fujii J, Phillips M, Korneluk R . Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature. 1990; 343(6258):559-61. DOI: 10.1038/343559a0. View

18.

McCarthy T, Healy J, Heffron J, Lehane M, Deufel T, Lehmann-Horn F . Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature. 1990; 343(6258):562-4. DOI: 10.1038/343562a0. View

19.

Weber J, May P, Kappel C . Dinucleotide repeat polymorphism at the D19S49 locus. Nucleic Acids Res. 1990; 18(7):1927. PMC: 330650. DOI: 10.1093/nar/18.7.1927. View

20.

Harbitz I, Chowdhary B, Thomsen P, Davies W, Kaufmann U, Kran S . Assignment of the porcine calcium release channel gene, a candidate for the malignant hyperthermia locus, to the 6p11----q21 segment of chromosome 6. Genomics. 1990; 8(2):243-8. DOI: 10.1016/0888-7543(90)90278-3. View